Your browser doesn't support javascript.
loading
CalliSpheres® drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study.
Zhang, X; Zhou, J; Zhu, D-D; Huang, J; Sun, J-H; Li, T-F; Shi, C-S; Sun, Z-C; Hou, Q-M; Peng, Z-Y; Yu, W-Q; Ji, J-S; Gu, W-J; Zhou, G-H; Xie, X-X; Guo, X-H; Cao, G-H; Yu, Z-H; Xu, H-H; Fang, J; Ying, S-H; Hu, W-H; Ji, W-B; Han, J; Wu, X; Zheng, J-P; Luo, J; Chen, Y-T; Hu, T-Y; Li, L; Hu, H-J; Du, H-J; Shao, G-L.
Afiliação
  • Zhang X; Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
  • Zhou J; Department of Radiology, Hangzhou Cancer Hospital, No. 34 Yan Guan lane, Hangzhou, China.
  • Zhu DD; Department of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.
  • Huang J; Department of Hepatobiliary Surgery, Ningbo Medical Center Lihuili Easter Hospital, No. 1111 Jiangnan Road, Ningbo, 315000, China.
  • Sun JH; Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
  • Li TF; Department of Radiology, Beilun District People's Hospital of Ningbo, No. 1288 Lushang East Road, Ningbo, 315826, China.
  • Shi CS; Department of Intervention, Ruian People's Hospital, The Third Affiliated Hospital of Wenzhou Medical University, No. 108 Wansong Road, Ruian, 325200, China.
  • Sun ZC; Department of Radiology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Hospital of TCM, No. 54 Youdian Road, Hangzhou, 310006, China.
  • Hou QM; Department of Radiology, Xixi Hospital of Hangzhou, Hangzhou 6th People's Hospital, Hengbu Street 2, Hangzhou, 310023, China.
  • Peng ZY; Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
  • Yu WQ; Department of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.
  • Ji JS; Department of Radiology, Lishui Central Hospital, Lishui Hospital of Zhejiang University, The Fifth Affiliated Hospital of Wenzhou Medical University, No. 289 Kuocang Road, Lishui, 323000, China.
  • Gu WJ; Department of Intervention, Jiaxing Second Hospital, No. 1518 Huangcheng North Road, Jiaxing, 314000, China.
  • Zhou GH; Division of Hepatobiliary and Pancreatic Surgery, Hepatobiliary and Pancreatic Interventional Treatment Center, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
  • Xie XX; Interventional Center, Xinchang People's Hospital, No. 117 Gushan Road, Xinchang, 312500, China.
  • Guo XH; Department of Intervention, Jinhua Municipal Central Hospital, Jinhua Hospital of Zhejiang University, No. 365 Renmin East Road, Jinhua, 321000, China.
  • Cao GH; Department of Radiology, Shulan (Hangzhou) Hospital, No. 848 Dongxin Road, Hangzhou, 310026, China.
  • Yu ZH; Department of Vascular and Interventional Radiology, The Affiliated Hospital of Medical School of Ningbo University, No. 247 Renmin Road, Ningbo, 315020, China.
  • Xu HH; Division of Digestive Endoscopy, Yueqing City People's Hospital, No. 338 Qingyuan Road, Yueqing, 325600, China.
  • Fang J; Department of Hepatobiliary Surgery, Quzhou People's Hospital, No. 2 Zhongloudi, Quzhou, 324000, China.
  • Ying SH; Interventional Radiology Department, The First Affiliated Hospital, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310006, China.
  • Hu WH; Department of Intervention, The First Provincial Wenzhou Hospital of Zhejiang, The First Affiliated Hospital of Wenzhou Medical University, No. 2 Fuxue Lane, Wenzhou, 325099, China.
  • Ji WB; Department of Radiology, Taizhou Hospital of Zhejiang Province, No. 150 Ximen Street, Linhai, 317000, China.
  • Han J; Department of Intervention, Jiaxing First Hospital, No. 1882 Zhonghuan South Road, Jiaxing, 314001, China.
  • Wu X; Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.
  • Zheng JP; Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
  • Luo J; Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
  • Chen YT; Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China.
  • Hu TY; Department of Intervention, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, No. 158 Shangtang Road, Hangzhou, 310000, China.
  • Li L; Department of Liver Oncology, Ningbo No. 2 Hospital, No. 41 Xibei Road, Ningbo, 315010, China.
  • Hu HJ; Department of Radiology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Road, Hangzhou, 310016, China.
  • Du HJ; Department of Intervention, Dongyang People's Hospital, No. 60 Wuning West Road, Dongyang, 322100, China. 425183318@qq.com.
  • Shao GL; Department of Intervention, Zhejiang Cancer Hospital, No. 1 Banshan East Road, Hangzhou, 310022, China. shaoguoliang1@163.com.
Clin Transl Oncol ; 21(2): 167-177, 2019 Feb.
Article em En | MEDLINE | ID: mdl-30003530
ABSTRACT

PURPOSE:

To assess the efficacy and safety of drug-eluting beads transarterial chemoembolization (DEB-TACE) in liver cancer patients with different times of previous conventional transarterial chemoembolization (cTACE) treatments.

METHODS:

367 liver cancer patients about to receive DEB-TACE treatment were enrolled in this prospective cohort study. All patients were divided into no previous cTACE group (NPC group), 1-2 times previous cTACE group (PC group) and triple or above previous cTACE group (TPC group) according to the times of previous cTACE treatments.

RESULTS:

There was no difference in complete response (CR) (P = 0.671) and objective response rate (ORR) (P = 0.062) among three groups. Additionally, no difference in overall survival (OS) among groups (P = 0.899) was found. As to liver function, most liver function indexes were deteriorative at 1 week after DEB-TACE operation, but returned to baseline at 1-3 months after DEB-TACE operation in all three groups, while percentage of abnormal total bile acid (TBA) patients was higher in TPC group than NPC and PC groups at 1-3 month post-DEB-TACE (P = 0.018). As for safety profiles, the incidence of pain during DEB-TACE operation was lower in TPC group compared to NPC and PC groups (P = 0.005), while no difference of other adverse events was found during and 1 month post-DEB-TACE treatment among three groups.

CONCLUSION:

DEB-TACE treatment was equally efficient and tolerated in liver cancer patients with different times of previous cTACE treatments.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doxorrubicina / Quimioembolização Terapêutica / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Doxorrubicina / Quimioembolização Terapêutica / Neoplasias Hepáticas / Antibióticos Antineoplásicos Tipo de estudo: Clinical_trials / Observational_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China